血清FGF19、IL-17及LP(a)对预测1型糖尿病患者微血管病变的价值

本研究旨在初步分析1型糖尿病患者血清FGF19、IL-17及LP(a)水平对患者微血管病变的预测价值,选取了1型糖尿病患者206例纳入研究并收集患者血清标本,采用酶联免疫法测定FGF19、IL-17及LP(a)水平。结果显示,1型糖尿病患者的FGF19、IL-17及LP(a)水平增高,不同年龄组患者的FGF19、IL-17及LP(a)水平有统计学差异,且FGF19水平与LP(a)水平呈正相关,LP(a)水平与IL-17水平呈正相关。此外,联合检测FGF19、IL-17及LP(a)水平对预测微血管病变比单独检测FGF19对预测微血管病变具有一定的筛检价值。结果提示,检测FGF19、IL-17及LP(a)水平对评估1型糖尿病患者的病情有重要临床意义；单独检测FGF19抗体以及联合检测三种指标均可预测微血管病变。

The value of serum FGF19, IL-17 and LP in type 1 diabetic patients for predicting themicrovascular disease

The purpose of this study was to preliminarily analyze the predictive value of serum FGF19, IL-17 and LP(a) levels in patients with type 1 diabetes mellitus for patients with microangiopathy. 206 patients with type 1 diabetes were enrolled in the study and serum samples were collected. The levels of FGF19, IL-17 and LP(a) were measured by enzyme-linked immunosorbent assay (ELISA) and analyzed for their association with the prognosis of microangiopathy. The FGF19, IL-17 and LP(a) levels were higher in the pateints, and the FGF19, IL-17 and LP(a) levels were different in different age. There was a positive correlation with LP(a) level, and LP(a) level was positively correlated with IL-17 level. In addition, the combined detection of fibroblast growth factor 19, IL-17 and LP (a) levels has a good screening value than that of the detection of fibroblast growth factor 19 alone. Therefore, FGF19, IL -17 and LP(a) levels are important to evaluate the condition of type 1 diabetes mellitus, and the detection of FGF19 antibody alone and the combined detection of these indicators can predict microangiopathy.